Institute for Wealth Management LLC. decreased its holdings in Danaher Co. (NYSE:DHR – Free Report) by 6.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,304 shares of the conglomerate’s stock after selling 223 shares during the period. Institute for Wealth Management LLC.’s holdings in Danaher were worth $758,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. FMR LLC boosted its stake in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. grew its holdings in Danaher by 0.6% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after acquiring an additional 9,942 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Transactions at Danaher
In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 11.10% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Analysis on Danaher
Danaher Stock Down 0.2 %
Shares of Danaher stock opened at $222.56 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market capitalization of $160.75 billion, a PE ratio of 42.15, a price-to-earnings-growth ratio of 4.22 and a beta of 0.83. Danaher Co. has a 52-week low of $221.34 and a 52-week high of $281.70. The company has a 50-day simple moving average of $235.66 and a two-hundred day simple moving average of $253.24.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period in the previous year, the firm earned $2.09 earnings per share. On average, analysts anticipate that Danaher Co. will post 8.15 EPS for the current fiscal year.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.49%. Danaher’s dividend payout ratio is presently 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- How to Read Stock Charts for Beginners
- Nebius Group: Market Overreaction or Real AI Disruption?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- The Best Way to Invest in Gold Is…
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.